LNTH: FDA Issues CRL
Lantheus Holdings shares are trading lower after the FDA issued a Complete Response Letter regarding its New Drug Application For LNTH-2501
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.